PNC Financial Services Group
ZNTL icon

PNC Financial Services Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

PNC Financial Services Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28
Closed -$32 – 5246
2025
Q2 		$32 Sell
28
-588
-95% -$776 ﹤0.01% 4877
2025
Q1 		$980 Buy
616
+466
+311% +$1K ﹤0.01% 4522
2024
Q4 		$455 Buy
150
+128
+582% +$419 ﹤0.01% 4543
2024
Q3 		$81 Hold
22
– – ﹤0.01% 4731
2024
Q2 		$90 Buy
+22
New +$246 ﹤0.01% 4720
2022
Q1 		– Sell
-16
Closed -$2K – 4727
2021
Q4 		$2K Hold
16
– – ﹤0.01% 4197
2021
Q3 		$2K Buy
+16
New +$923 ﹤0.01% 4145

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PNC Financial Services Group's ZNTL Position: Q3 2025 in Review

PNC Financial Services Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 28 shares — an estimated $32 sold.

PNC Financial Services Group first reported a position in ZNTL in Q3 2021 and held it in 7 quarters. The position peaked at $2K in Q4 2021. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • PNC Financial Services Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 28 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $32.
  • PNC Financial Services Group first reported a position in Zentalis Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • PNC Financial Services Group's Zentalis Pharmaceuticals position peaked at $2K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.